摘要
目的:研究不同剂量氨溴索口服液治疗糖尿病合并社区获得性肺炎(CAP)的疗效及安全性。方法:收治2型糖尿病合并CAP患者50例,随机分为对照组和治疗组各25例。对照组给予常规剂量氨溴索治疗,治疗组给予双倍剂量氨溴索治疗。对比两组患者治疗前后的炎症情况及不良反应。结果:治疗组的炎症改善情况明显优于对照组(P<0.05)。结论:双倍剂量氨溴索口服液治疗糖尿病合并CAP具有较好的疗效。
Objective:To study the curative effect and safety of different doses of ambroxol oral solution in the treatment of diabetes combined with community acquired pneumonia(CAP).Methods:50patients with type2diabetes combined with community acquired pneumonia were selected.They were randomly divided into the control group and the treatment group with25cases in each.The control group was given conventional dose of ambroxol treatment.The treatment group was given double dose of ambroxol treatment.The inflammation and adverse reactions before and after treatment were compared between groups.Results:The inflammation improvement of the treatment group was better than that of the control group(P<0.05).Conclusion:Double dose of ambroxol oral solution has a good curative effect in the treatment of diabetes combined with community acquired pneumonia.
作者
韩晓萍
Han Xiaoping(Department of Otorhinolaryngology,Beijing Zhongkangjia Traditional Chinese Medicine Institute(Changgeng Hospital) 100043)
出处
《中国社区医师》
2017年第14期53-53,55,共2页
Chinese Community Doctors
关键词
氨溴索口服液
糖尿病
社区获得性肺炎
Ambroxol oral solution
Diabetes
Community acquired pneumonia
